(PCI – a heart procedure to widen blocked blood vessels).
“These findings suggest for the first time that clopidogrel monotherapy is associated with a reduced risk of long-term NACE (true adverse clinical events) and MACCE (serious cardiac or brain events). Our results may have important practical implications for determining the optimal treatment for Hao-Yu Wang, Chinese Academy of Medical Sciences and Peking Union Medical University, Beijing, China. states that patients need a single antiplatelet agent, aspirin or clopidogrel, for the secondary prevention of ischemic events in a population at high risk for PCI.
The team recommends further randomized clinical trials to support their findings.
Source: Medindia
